Haridwar Today

Cystinosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Cystinosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 05
20:21 2021
Cystinosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
“Cystinosis Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the cystinosis market. A detailed picture of the cystinosis pipeline landscape is provided, which includes the disease overview and cystinosis treatment guidelines.

DelveInsight’s Cystinosis Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Cystinosis pipeline landscapes. It comprises Cystinosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cystinosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cystinosis pipeline products.     

Some of the key takeaways of the Cystinosis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, etc., are developing therapies for the treatment of Cystinosis.

  • Emerging therapies such as Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), are expected to have a significant impact on the  Cystinosis market in the coming years.

  • ELX-02 (formerly known as NB124) is a small molecule, administered by the parenteral subcutaneous (SC) route. The molecule is under investigation for the treatment of cystinosis. It is under Phase II clinical trial.

Get an overview of pipeline landscape @ Cystinosis Clinical Trials Analysis 

Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of cystine, the oxidized dimer of the amino acid cysteine. It is a genetic disorder that follows an autosomal recessive inheritance pattern.

For further information, refer to the detailed report @ Cystinosis Pipeline Therapeutics 

Cystinosis Emerging Drugs

  • Procysbi (cysteamine bitartrate) by Horizon Pharma

  • Cystadrops (cysteamine hydrochloride) by Recordati S.p.A.

  • Cystaran (cysteamine hydrochloride) by Leadiant Biosciences

  • Cystagon (cysteamine bitartrate) by Mylan Pharmaceuticals

Scope of Cystinosis Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, and others.

  • Pipeline Therapies: Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), and others.

Table of Contents

1

Cystinosis Report Introduction

2

Cystinosis Executive Summary

3

Cystinosis Overview

4

Cystinosis- Analytical Perspective In-depth Commercial Assessment

5

Cystinosis Pipeline Therapeutics

6

Cystinosis Late Stage Products (Phase II/III)

7

Cystinosis Mid Stage Products (Phase II)

8

Cystinosis Early Stage Products (Phase I)

9

Cystinosis Preclinical Stage Products

10

Cystinosis Therapeutics Assessment

11

Cystinosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Cystinosis Key Companies

14

Cystinosis Key Products

15

Cystinosis Unmet Needs

16 

Cystinosis Market Drivers and Barriers

17

Cystinosis Future Perspectives and Conclusion

18

Cystinosis Analyst Views

19

Appendix

20

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share